Physician profile
Nadim Dagher
NPI 1053531467
$7,022.66
in general payments reported to CMS, 2019-2025
31 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $214 · 2021: $361 · 2022: $586 · 2023: $1,403 · 2024: $1,492 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,066.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,417.01 | 2019-2025 | Otezla, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $806.08 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $510.26 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $442.39 | 2021-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $340.15 | 2022-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $283.23 | 2023-2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $269.90 | 2022-2025 | Zoryve, Livalo, Seglentis |
| Abbvie INC. | $237.62 | 2021-2025 | Vraylar |
| Pfizer INC. | $221.28 | 2019-2025 | |
| Horizon Therapeutics Plc | $200.90 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $177.99 | 2022-2025 | |
| Glaxosmithkline, LLC. | $152.59 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Biotech, INC. | $121.83 | 2024 | Simponi Aria, Tremfya |
| E.R. Squibb & Sons, L.L.C. | $117.45 | 2021-2024 | Eliquis |
| Esperion Therapeutics, INC. | $78.85 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $74.47 | 2025 | |
| Ardelyx, INC. | $72.27 | 2024-2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $58.81 | 2019 | |
| Corcept Therapeutics | $54.86 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $51.27 | 2019-2020 | |
| Vertiflex, INC. | $50.24 | 2019 | |
| Merck Sharp & Dohme LLC | $46.40 | 2019 | |
| Allergan, INC. | $42.62 | 2019 | |
| Exact Sciences Corporation | $41.35 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $39.63 | 2019 | |
| Sumitomo Pharma America, INC. | $26.89 | 2025 | Gemtesa |
| Abbott Laboratories | $24.67 | 2022 | |
| Amarin Pharma, INC. | $23.98 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $20.98 | 2023 | Evkeeza |
| Currax Pharmaceuticals LLC | $15.57 | 2025 | Contrave |
| Forte Bio-Pharma LLC | $1.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadim Dagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.